yellow fever vaccine

Reactions 1456 - 15 Jun 2013 Yellow fever vaccine Elevated liver enzymes and skin reaction: case report A 55-year-old man developed elevated liver enzymes and a skin reaction after receiving live attenuated yellow fever vaccine. The man, who had undergone a kidney transplant 19 years earlier, received yellow fever vaccine [dose and route not stated]. Shortly afterwards, he realised the risks associated with the vaccination and contacted his nephrologist. His liver enzymes were monitored. Eleven days postvaccination, his AST and ALT levels were 60 units/mL and 53 units/mL, respectively. The man received immune globulin to reduce the risk of yellow fever-associated viscerotropic disease. His AST and ALT levels were normal on postvaccination day 18; however, his total bilirubin level was elevated at 2.4 units/mL on day 25. On day 26, he reported what may have been an eczematous or urticarial reaction on his face, the symptoms resolved within 5 days. His total bilirubin, AST and ALT levels were all normal on day 47. At follow-up 8 months later, he had not experienced any long-term adverse events. Author comment: "These results suggest that [intravenous immune globulin] could be administered as a precaution against potential [yellow fever-associated viscerotropic disease] or other [yellow fever virus] vaccine-associated adverse events." Slifka MK, et al. Antiviral immune response after live yellow fever vaccination of a kidney transplant recipient treated with IVIG. Transplantation 95: e59-e61, No. 9, 15 May 2013. Available from: URL: http://dx.doi.org/10.1097/ TP.0b013e31828c6d9e - USA 803088544 1 Reactions 15 Jun 2013 No. 1456 0114-9954/10/1456-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Post on 23-Dec-2016

215 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Reactions 1456 - 15 Jun 2013

Yellow fever vaccine

Elevated liver enzymes and skin reaction: casereport

A 55-year-old man developed elevated liver enzymes and askin reaction after receiving live attenuated yellow fevervaccine.

The man, who had undergone a kidney transplant 19 yearsearlier, received yellow fever vaccine [dose and route notstated]. Shortly afterwards, he realised the risks associatedwith the vaccination and contacted his nephrologist. His liverenzymes were monitored. Eleven days postvaccination, hisAST and ALT levels were 60 units/mL and 53 units/mL,respectively.

The man received immune globulin to reduce the risk ofyellow fever-associated viscerotropic disease. His AST and ALTlevels were normal on postvaccination day 18; however, histotal bilirubin level was elevated at 2.4 units/mL on day 25. Onday 26, he reported what may have been an eczematous orurticarial reaction on his face, the symptoms resolved within5 days. His total bilirubin, AST and ALT levels were all normalon day 47. At follow-up 8 months later, he had not experiencedany long-term adverse events.

Author comment: "These results suggest that [intravenousimmune globulin] could be administered as a precautionagainst potential [yellow fever-associated viscerotropicdisease] or other [yellow fever virus] vaccine-associatedadverse events."Slifka MK, et al. Antiviral immune response after live yellow fever vaccination ofa kidney transplant recipient treated with IVIG. Transplantation 95: e59-e61, No.9, 15 May 2013. Available from: URL: http://dx.doi.org/10.1097/TP.0b013e31828c6d9e - USA 803088544

Instructions for Certified Yellow Fever Vaccine Provider ... Yellow Fever Vaccine... · Instructions for Certified Yellow Fever Vaccine Provider Application and Vaccination Site Agreement

Yellow Fever Vaccine - CDC

Yellow fever vaccine recommendations in Brazil¹ - cdc.gov · ³ Yellow fever (YF) vaccination is generally not recommended in areas where there is low potential for YF virus exposure

Attenuation of Live-Attenuated Yellow Fever 17D Vaccine Virus Is … · Concurrent to the development of the 17D vaccine virus, another live-attenuated YF vaccine, French neurotropic

Yellow fever vaccine and risk of developing serious

Background Paper on Yellow Fever Vaccine - World … 19 March 2013 Page 1 of 43 Background Paper on Yellow Fever Vaccine SAGE Working Group TABLE OF CONTENTS

Yellow Fever Vaccine - California Department of Public Health

Yellow fever vaccine recommendations in Peru¹ ¹ Current as ...CAJAMARCA LA Trujillo COLOMBIA Iquitos LORETO I Pacaya / — .%rniria / Yellow fever vaccine Vaccination recommended

Guide on Access to the Yellow Fever ICG Stockpile ... · approved the "Yellow Fever vaccine stockpile investment case", increasing significantly its support to reduce the risk of

Was gibt es Neues aus der Epidemiologie (et al.)? · YEL-AND = yellow fever vaccine associated neurotropic disease * = all cases occurred in primary yellow fever vaccinees ** = including

Yellow Fever Vaccine - Centers for Disease Control and ... · Yellow Fever Vaccine ... Leonard E. Munstermann, Yale School of Medicine. Reproduced with permission. Urban yellow fever

Who should get Yellow Fever vaccine